Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

ctDNA dynamics from 217 patients at six centers, training and validation. Before therapy, ctDNA was detectable in 98%; pretreatment levels were prognostic in front-line and salvage settings. In the first validation set, front-line patients achieving EMR or MMR had superior 24-month EFS (EMR 83% vs 50%, P=0.0015; MMR 82% vs 46%, P<.001). EMR also predicted salvage 24-month EFS (100% vs 13%, P=0.011). Molecular response was independently prognostic including after adjustment for IPI and interim PET/CT. Level 2.

J Clin OncolPubMed 30125215